Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2024
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867015504118415360 |
|---|---|
| author | Benjamin J. Lee Jenny Liu Shawn P. Griffin Jean Doh Stefan O. Ciurea Piyanuch Kongtim Elizabeth A. Brem |
| author_facet | Benjamin J. Lee Jenny Liu Shawn P. Griffin Jean Doh Stefan O. Ciurea Piyanuch Kongtim Elizabeth A. Brem Benjamin J. Lee Jenny Liu Shawn P. Griffin Jean Doh Stefan O. Ciurea Piyanuch Kongtim Elizabeth A. Brem |
| collection | Wiley Open Access |
| contents | Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies Benjamin J. Lee Jenny Liu Shawn P. Griffin Jean Doh Stefan O. Ciurea Piyanuch Kongtim Elizabeth A. Brem Cancer Medicine ABSTRACTIntroductionBlastoid variant‐mantle cell lymphoma (BV‐MCL) represents an aggressive subset of patients with no established standard of care treatment approach.MethodsWe performed a retrospective analysis of the clinical characteristics and outcomes of 17 de novo BV‐MCL patients treated at our institution between May 2009 and September 2023. In addition, we reviewed the literature supporting 2nd/3rd generation Bruton's Tyrosine‐kinase (BTKi)‐based therapies for upfront management.ResultsThe complete response rate to frontline and salvage therapy was 66.7% and 25%, respectively. Two‐year overall survival (OS) was low at 62.5% (95% CI, 34.7%–81.1%). Variables associated with higher OS included receipt of consolidative HSCT (p = 0.017), TP53‐wild type (p = 0.031), intermediate‐ versus high‐risk Mantle Cell Lymphoma Prognostic Index score (p = 0.026), and achieving complete response with induction therapy (p = 0.027).DiscussionTreatment outcomes with chemo‐immunotherapy in BV‐MCL patients are poor, especially among TP53‐mutated patients. Recent findings describing positive outcomes with novel BTKi‐based therapies are encouraging and should be considered in this high‐risk population. 10.1002/cam4.70310 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/cam4.70310 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_cam4_70310 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies Benjamin J. Lee Jenny Liu Shawn P. Griffin Jean Doh Stefan O. Ciurea Piyanuch Kongtim Elizabeth A. Brem Cancer Medicine Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies Benjamin J. Lee Jenny Liu Shawn P. Griffin Jean Doh Stefan O. Ciurea Piyanuch Kongtim Elizabeth A. Brem Cancer Medicine ABSTRACTIntroductionBlastoid variant‐mantle cell lymphoma (BV‐MCL) represents an aggressive subset of patients with no established standard of care treatment approach.MethodsWe performed a retrospective analysis of the clinical characteristics and outcomes of 17 de novo BV‐MCL patients treated at our institution between May 2009 and September 2023. In addition, we reviewed the literature supporting 2nd/3rd generation Bruton's Tyrosine‐kinase (BTKi)‐based therapies for upfront management.ResultsThe complete response rate to frontline and salvage therapy was 66.7% and 25%, respectively. Two‐year overall survival (OS) was low at 62.5% (95% CI, 34.7%–81.1%). Variables associated with higher OS included receipt of consolidative HSCT (p = 0.017), TP53‐wild type (p = 0.031), intermediate‐ versus high‐risk Mantle Cell Lymphoma Prognostic Index score (p = 0.026), and achieving complete response with induction therapy (p = 0.027).DiscussionTreatment outcomes with chemo‐immunotherapy in BV‐MCL patients are poor, especially among TP53‐mutated patients. Recent findings describing positive outcomes with novel BTKi‐based therapies are encouraging and should be considered in this high‐risk population. 10.1002/cam4.70310 http://creativecommons.org/licenses/by/4.0/ |
| title | Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies |
| topic | Cancer Medicine |
| url | https://onlinelibrary.wiley.com/doi/10.1002/cam4.70310 |